Stockscreener 앱 받기
86.33
3.79%
3.15
시간 외 거래:
86.43
0.10
+0.12%
Ionis Pharmaceuticals Inc 주식(IONS)의 최신 뉴스
[144] IONIS PHARMACEUTICALS INC SEC Filing - Stock Titan
IONS (Nasdaq: IONS) brokered notice to sell 67,386 shares - Stock Titan
Holly Kordasiewicz files Form 144 to sell 60,846 shares (IONS) - Stock Titan
IONS Completes Enrollment in Pivotal Cohort of Angelman Syndrome Study - Yahoo Finance
Ionis Pharmaceuticals stock leans on pipeline and Nasdaq trading - AD HOC NEWS
Novartis’ Pipeline Building Continues, Pelacarsen Readout Coming Soon (NYSE:NVS) - Seeking Alpha
Transthyretin Amyloidosis Treatment Market Size to Reach USD 35.10 Billion by 2035, Growing at a 14.64% CAGR | SNS Insider - GlobeNewswire Inc.
Ionis Pharmaceuticals concludes REVEAL study pivotal cohort enrolment - Clinical Trials Arena
Amyotrophic Lateral Sclerosis Market Trends, Innovation, and Future Growth Outlook to 2036 – DelveInsight | Helixmith, Sanofi, Denali Therapeutics, Transposon Therapeutics, GSK, Biogen, Ionis Pharma - Barchart.com
Ionis Pharmaceuticals director Joseph Klein III sells $910k in stock - Investing.com Canada
Ionis (NASDAQ: IONS) director receives $400K-capped RSUs and options grant - Stock Titan
Form 4 Ionis Pharmaceuticals Inc For: 6 July By Investing.com - Investing.com Canada
Ionis (NASDAQ: IONS) awards director RSUs and stock options - Stock Titan
Ionis (NASDAQ: IONS) director receives 2026 RSU and stock option grants - Stock Titan
Ionis (NASDAQ: IONS) director receives 2026 RSU and stock option awards - Stock Titan
Ionis Pharmaceuticals (IONS) grants director RSUs and stock options - Stock Titan
Ionis Pharmaceuticals Advances Obudanersen for Angelman Syndrome - GuruFocus
Ionis finishes patient enrollment in Phase 3 rare disease trial - grafa.com
Ionis Pharmaceuticals, Inc. Completes Enrollment in Pivotal Cohort of Phase 3 REVEAL Study Evaluating Obudanersen in Angelman Syndrome - marketscreener.com
Ionis completes enrollment in Angelman syndrome drug trial - Investing.com UK
Ionis Pharmaceuticals (IONS) Advances Phase 3 REVEAL Study for A - GuruFocus
Ionis completes enrollment in Angelman syndrome drug trial By Investing.com - Investing.com Canada
Ionis completes enrollment in pivotal cohort of the Phase 3 REVEAL study evaluating obudanersen in Angelman syndrome - Business Wire
Ionis Pharmaceuticals, Inc. (IONS) Stock Analysis: Exploring a 29.48% Potential Upside in the Biotech Sphere - DirectorsTalk Interviews
IONS out-licenses ex-US rights for rare neurology drug to Recordati - MSN
IONS News | IONIS PHARMACEUTICALS INC (NASDAQ:IONS) - ChartMill
TimesSquare Mid Cap Growth Strategy Picks Ionis Pharmaceuticals (IONS) on Clinical Momentum - Yahoo Finance
Form 144 IONIS PHARMACEUTICALS INC For: 1 July By Investing.com - Investing.com India
IONSIonis Pharmaceuticals Inc Latest SEC Filings - Finviz
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock - Investing.com UK
Ionis Pharmaceuticals EVP Joseph Baroldi’s spouse sells $451,698 stock - Investing.com UK
Ionis Pharmaceuticals EVP Joseph Baroldi’s spouse sells $451,698 stock By Investing.com - Investing.com Nigeria
Ionis Pharmaceuticals EVP Schneider sells $2.1m in stock By Investing.com - Investing.com Nigeria
Form 4 Ionis Pharmaceuticals Inc For: 30 June By Investing.com - Investing.com Canada
Spouse of Ionis (NASDAQ: IONS) EVP exercises options and sells shares - Stock Titan
Trump's push for the world's lowest drug prices hits snag with mid-sized companies - marketscreener.com
Ionis Pharmaceuticals (IONS) Signs Recordati Deal For Zilganersen Outside The U.S. - Yahoo Finance
Why Ionis Pharmaceuticals (IONS) Is Up 9.5% After Dual TRYNGOLZA Approval and Zilganersen Out-Licensing Deal - Sahm
Ionis Pharmaceuticals (IONS) Is Up 9.5% After FDA Expands Tryngolza Label For Severe Hypertriglyceridemia - Yahoo Finance
Price to book forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Enterprise value to EBITDA forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV) and Ionis Pharmaceuticals (IONS) - The Globe and Mail
Insider Sell: Brett Monia Sells 85,637 Shares of Ionis Pharmaceu - GuruFocus
Form 144 IONIS PHARMACEUTICALS INC For: 26 June - Investing.com UK
Ionis (IONS) Wins Tryngolza Approval And Recordati Deal For Zilganersen - Sahm
Ionis CEO Brett Monia sells $6.8 million in company shares By Investing.com - Investing.com Nigeria
Price to earnings forward of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – NASDAQ:IONS - TradingView
(IONS) Movement as an Input in Quant Signal Sets - Stock Traders Daily
Form 144 IONIS PHARMACEUTICALS INC For: 26 June By Investing.com - Investing.com South Africa
Enterprise value to revenue forward of Ionis Pharmaceuticals, Inc. – SWB:ISI - TradingView
Ionis Pharmaceuticals EVP research Eric Swayze sells $839k in stock By Investing.com - Investing.com Australia
Ionis Pharmaceuticals EVP research Eric Swayze sells $839k in stock - Investing.com Australia
Form 4 Ionis Pharmaceuticals Inc For: 26 June By Investing.com - Investing.com Nigeria
Ionis CEO Brett Monia sells $6.8 million in company shares - Investing.com
Ionis Pharmaceuticals, Inc. Actuals & Estimates (HAM:ISI) - TradingView
Ionis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:IONS) - TradingView
Form 144 | Ionis Pharmaceuticals(IONS.US) Officer Proposes to Sell 3.88 Million in Common Stocks - Moomoo
Ionis Pharmaceuticals, Inc. Actuals & Estimates (DUS:ISI) - TradingView
1.17%
2.48%
자본화:
|
볼륨(24시간):